Deutsche Bank AG Has $5.34 Million Stake in Privia Health Group, Inc. (NASDAQ:PRVA)

Deutsche Bank AG raised its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 11.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 272,973 shares of the company's stock after purchasing an additional 28,556 shares during the period. Deutsche Bank AG owned approximately 0.23% of Privia Health Group worth $5,337,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Durable Capital Partners LP increased its stake in Privia Health Group by 3.4% in the fourth quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company's stock valued at $224,587,000 after purchasing an additional 378,255 shares in the last quarter. Bank of America Corp DE increased its position in shares of Privia Health Group by 5.1% during the fourth quarter. Bank of America Corp DE now owns 1,021,763 shares of the company's stock worth $19,975,000 after acquiring an additional 49,389 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Privia Health Group during the fourth quarter worth $4,321,000. Algert Global LLC increased its position in shares of Privia Health Group by 639.1% during the fourth quarter. Algert Global LLC now owns 108,048 shares of the company's stock worth $2,112,000 after acquiring an additional 93,429 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its position in shares of Privia Health Group by 20.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 300,000 shares of the company's stock worth $5,865,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors own 94.48% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on PRVA shares. Truist Financial increased their price objective on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Thursday, April 10th. Robert W. Baird increased their price objective on shares of Privia Health Group from $24.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 15th. Piper Sandler increased their price objective on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group increased their price objective on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Privia Health Group has a consensus rating of "Buy" and a consensus target price of $27.38.

Privia Health Group Price Performance

PRVA stock traded down $0.70 during trading hours on Thursday, reaching $23.10. The stock had a trading volume of 864,345 shares, compared to its average volume of 744,818. The stock has a market capitalization of $2.82 billion, a PE ratio of 231.02, a price-to-earnings-growth ratio of 3.47 and a beta of 0.87. The stock has a 50-day simple moving average of $23.41 and a 200 day simple moving average of $22.63. Privia Health Group, Inc. has a fifty-two week low of $16.00 and a fifty-two week high of $26.09.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, CEO Parth Mehrotra sold 13,773 shares of the stock in a transaction on Monday, May 12th. The shares were sold at an average price of $24.99, for a total value of $344,187.27. Following the completion of the sale, the chief executive officer now owns 423,143 shares in the company, valued at $10,574,343.57. This trade represents a 3.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO David Mountcastle sold 3,445 shares of the stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $80,371.85. Following the completion of the sale, the chief financial officer now owns 176,231 shares of the company's stock, valued at approximately $4,111,469.23. This represents a 1.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 51,579 shares of company stock worth $1,226,367 over the last quarter. 10.70% of the stock is currently owned by insiders.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.